The interest in functional and medically effective mushrooms is increasing rapidly worldwide and the prospects for the sector are accordingly excellent. So does the cannabis and hemp extraction society Pure Extracts Technologies (CSE PULL / WKN A2QJAJ) recognized and is pressing ahead with entry into this promising market.
As Pure Extracts notes, there has recently been increased institutional interest in the field of psychedelics in general and in promising fungal active ingredients such as psilocybin in particular. Psilocybin is currently being used in numerous studies regarding its treatment potential, among others examined in depression, anxiety, post-traumatic stress disorder, bipolar disorder, Alzheimer’s disease and addictions. And the attitude of the US FDA (Food and Drug Administration) also seems to be softening after the first research successes had already been achieved this year. According to the latest reports, the market for functional mushrooms is expected to reach a total volume of USD 34.3 billion by 2024, with a respectable growth of 8% per year!
No wonder, then, that Pure Extracts is tackling the expansion of the business model into the area of mushroom formulations, using extraction processes that have been proven to be compatible with the company’s existing infrastructure. The company works closely with its scientific advisor Dr. Alexander MacGregor, founder of the Toronto Institute of Pharmaceutical Technology, to develop bioavailable products and novel delivery methods such as tablets, capsules and edibles.
Agreement with leading Canadian mushroom brand
Pure Extracts also sees a great opportunity to become a major extraction partner in the commercialization of functional mushroom products – and has already signed a letter of intent with one of Canada’s leading wellness and mushroom brands! The aim is to work with the new partner to develop improved mushroom products by adding CBD (cannabidiol).
Entering the growing field of processing psychedelically active mushrooms as part of the strategy for penetrating various extraction markets is only a later step. First of all, Pure Extracts wants to create three functional products using mushroom varieties such as “lion’s mane”, the vital mushroom Coriolus and Reishi. In herbal medicine, these products are viewed as memory-enhancing, stress-relieving, or immune system support.
The company expects to be able to offer these products via its own e-commerce platform as early as the end of the first quarter of 2021. The creation of these products under the brand name Pure Mushrooms is not only intended to generate revenue, it is also intended to validate the practices and capabilities of Pure Extracts and prepare additional products.
CEO Ben Nikolaevsky sums up the approach: “The entry into mushroom extraction is an obvious and exciting opportunity to effectively use our advanced technology and proven skills.” Legalization as both medicine and luxury goods. Like us, Mr. Nikolaevsky believes that immediate entry into this emerging sector has the potential to create “immense” values for everyone involved! We will continue to report.
Subscribe to our free newsletter: https://goldinvest.de/newsletter
Visit us on Twitter: https://twitter.com/GOLDINVEST_de
In accordance with Section 34b WpHG and Section 48f Paragraph 5 BörseG (Austria), we would like to point out that partners, authors and / or employees of GOLDINVEST Consulting GmbH can hold shares in Pure Extracts Technologies and thus a conflict of interest could exist. Furthermore, we cannot rule out that other stock market letters, media or research firms will discuss the values we have discussed during the same period. Therefore, symmetrical generation of information and opinions can occur during this period. Furthermore, there is a consulting or other service contract between GOLDINVEST Consulting GmbH and a third party in the issuer’s warehouse (Pure Extracts Technologies), which creates a conflict of interest, especially since this third party grants GOLDINVEST Consulting GmbH for a fee for reporting Pure Extracts Technologies rewards. This third party may also hold, sell or buy shares in the issuer and would benefit from an increase in the price of Pure Extracts Technologies shares. This is another conflict of interest.
PERSONAL-FINANCIAL.COM publishes analyzes, columns and news from various sources in this section.
PERSONAL-FINANCIAL.COM AG is not responsible for content that is recognizable by third parties in the “News” area
This website has been discontinued and does not adopt it as its own. These contents are in particular through
a corresponding “from” mark below the article heading and / or through the link
“To read the full article, please click here.” responsible for
this content is solely the named third party.